Track your weight-loss progress before each renewal to ensure you meet the reauthorization threshold
For researchers evaluating peptide options for weight loss , the speed factor may be as important as the total magnitude of effect
Um estudo de fase II, conduzido com adultos com obesidade ao longo de 48 semanas e publicado no New England Journal of Medicine em 2023, comparou diferentes doses de retatrutida com placebo
Article Information Published Online: May 15, 2025
People who use Zepbound or Mounjaro, the dual-agonist medications, lose an average of about 20% of their body weight, while those who take Ozempic or Wegovy, the single-agonist drugs, lost an average of about 14% of their body weight
Melanie Speed, APRN, NP-C , takes pride in providing our clients with the latest innovations in wellness, including advanced weight management solutions like GLP-1 therapies